多基因甲基化在骨髓增生异常综合征患者中的预后价值

发布时间：2018-02-04 08:00

  本文关键词： 骨髓增生异常综合征 DNA甲基化 多基因甲基化 预后价值　出处：《中国实验血液学杂志》2017年04期 　论文类型：期刊论文

【摘要】：目的:分析p15、DAPK、SOCS1和FHIT基因在骨髓增生异常综合征(MDS)患者中的甲基化状况,探讨基因甲基化在MDS中的预后价值。方法:应用甲基化特异性PCR(MSP)对67例MDS患者骨髓进行上述4种基因甲基化的检测,选择18例缺铁性贫血患者作为对照,分析MDS患者基因甲基化状况及其对生存率的影响。结果:67例M DS患者中p15、DAPK、SOCS1和FHIT 4种基因甲基化率分别为37.3%、35.8%、47.8%和52.2%,较对照组显著增高(P0.05);随着国际预后积分系统(IPSS)评分的增加,p15、SOCS1基因甲基化率呈增高趋势(P0.05),同时表达≥2个基因甲基化更易见于相对高危组患者(P0.05)。生存分析显示,有基因甲基化和无基因甲基化患者的中位生存时间分别为15和21个月(P0.05),在相对低危组中SCOS1基因甲基化患者生存时间短于非甲基化患者(P0.05),在相对高危组中SOCS1、p15及≥2个基因甲基化患者生存时间明显短于非甲基化患者(P0.05)。多因素分析显示,SOCS1及p15基因甲基化是MDS患者预后不良的影响因素。结论:p15、DAPK、SOCS1和FHIT是M DS中出现较高的甲基化基因,SOCS1及p15基因甲基化是M DS患者不良预后的独立危险因素。
[Abstract]:Objective: to analyze the methylation of p15 DAPKG SOCS1 and FHIT gene in patients with myelodysplastic syndrome (MDS). To evaluate the prognostic value of gene methylation in MDS methods: methylation specific PCR- MSPs were used to detect the methylation of bone marrow of 67 patients with MDS. Eighteen patients with iron deficiency anemia were selected as control group to analyze the status of gene methylation and its influence on survival rate in MDS patients. Results p15DAPK was found in 67 patients with MDS. The methylation rates of SOCS1 and FHIT were 37.3% and 52.2%, respectively, which were significantly higher than those of the control group (P 0.05). With the increase of IPSS score, the methylation rate of p15 SOCS1 gene showed an increasing trend (P0.05). At the same time, the methylation of more than 2 genes was more easily seen in the patients with higher risk group (P 0.05). Survival analysis showed that methylation of more than 2 genes was more common. The median survival time of patients with and without gene methylation was 15 and 21 months respectively (P0.05). The survival time of SCOS1 gene methylation patients was shorter than that of demethylated patients in the relatively low risk group, and SOCS1 was found in the relatively high risk group. The survival time of p15 and 鈮，

本文编号：1489759